TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Wee

Go back to TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Wee
ASTRAZENECA PLC (NASDAQ: AZN) Delayed: 92.77 --0 (-0%)
Previous Close $92.77    52 Week High $35.04 
Open $92.77    52 Week Low $26.97 
Day High $92.77    P/E N/A 
Day Low $92.77    EPS $0.00 
Volume 1,896,872